Bio-techne (TECH) Stock
Life science tools provider for research and diagnostics. Here's the price, business snapshot, and what's worth knowing about Bio-techne in October 2026.
Bio-Techne Corporation (TECH) supplies reagents, instruments and services used in life-science research, diagnostics and biopharma development. Investors should know it primarily sells consumables and specialised instruments to research organisations, pharmaceutical companies and clinical labs — a mix that can provide recurring revenue from consumables alongside more cyclical instrument sales. Growth has been driven by new product introductions, recurring demand for assays and reagents, and periodic acquisitions that expand capability and geographic reach. Key risks include sensitivity to research and R&D spending cycles, competitive pressure from other suppliers, supply-chain disruptions and regulatory or reimbursement shifts that can affect diagnostic adoption. The company’s market capitalisation is about $9.88bn, which positions it as a mid‑cap player in the life‑sciences tools space. This summary is educational, not investment advice: values can rise and fall and past performance is not a guarantee of future results. Review the latest financial reports and consider your own circumstances before deciding.
Bio-techne (TECH) Stock Forecast
Analyst price target, next 12 months
$77.81
+7.5% vs today's $72.40
Price range over the last 12 months
Close to its 12-month high
Analysts covering Bio-techne have a consensus 12-month target of $77.81, above the current price of $72.40.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping BIO-TECHNE's stock for now, with a target price indicating possible growth.
Financial Health
BIO-TECHNE is performing well with strong revenue, profits, and cash flow indicators.
Dividend
BIO-TECHNE CORP's dividend yield of 0.44% is lower than typical dividend-paying stocks. If you invested $1000 you would be paid $4.40 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Research tools demand
Rising R&D spending and biotech activity can support steady demand for reagents and assays, though demand can fluctuate with research budgets.
Diversified customer base
Sales to academic, biotech, pharma and clinical labs can smooth revenue, but geographic and customer concentration risks remain.
M&A and innovation
Acquisitions and product launches can accelerate capability and growth, but integration and execution risks should be monitored.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
